Naval G. Daver, MD

Articles

Dr Daver on the Potential Utility of Uproleselan in R/R AML

September 3rd 2024

Naval G. Daver, MD, discusses the potential utility of uproleselan in relapsed/refractory acute myeloid leukemia.

Dr Daver on the Targeted Therapy Development Pipeline in AML

May 1st 2024

Naval G. Daver, MD, discusses the future of targeted therapy development for patients with acute myeloid leukemia.

Dr Daver on the Investigation of Uproleselan Plus Azacitidine and Venetoclax in AML

September 22nd 2023

Naval G. Daver, MD, discusses the rationale for an ongoing phase 1 trial investigating uproleselan in combination with azacitidine and venetoclax in patients with treatment-naïve acute myeloid leukemia.

Optimizing Treatment Selection for Patients with FLT3-ITD AML

July 24th 2023

Discussion centered around optimal strategies to effectively treat, and improve outcomes for, patients with FLT3-ITD AML.

Standard Approach to Treatment for Fit Patients with Newly Diagnosed AML

July 17th 2023

Recommendations for community oncologists concerning the treatment of fit patients diagnosed with AML.

Clinical Insights Concerning Molecular Testing in Patients Diagnosed with Acute Myeloid Leukemia

July 17th 2023

Eunice S. Wang, MD opens a discussion with other panelists concerning the benefits of germline testing in AML, NCCN guidelines for molecular testing, and how molecular testing in AML is advancing over time.

An Introduction to Biomarker Testing in Acute Myeloid Leukemia

June 26th 2023

Experienced clinicians highlight the role of biomarker testing in AML for optimal patient care and treatment selection.

An Overview of Incidence, Diagnosis, and Subtype Classification in Acute Myeloid Leukemia

June 26th 2023

Moderator Naval G. Daver, MD introduces expert panelists and leads an overview of Acute Myeloid Leukemia, focusing on the importance of timely diagnosis and risk assessment for patients with AML.

Dr. Daver on the Use of ADCs in BPDCN

January 25th 2023

Naval Daver, MD, discusses the use of antibody-drug conjugates (ADC) in the treatment of patients with blastic plasmacytoid dendritic cell neoplasm.

Dr. Daver on the Next Steps for Menin Inhibitors in AML

December 17th 2021

Naval Daver, MD, discusses the next steps for menin inhibitors in acute myeloid leukemia.

Dr. Daver on the Tolerability of Magrolimab Plus Azacitidine in AML/MDS

August 29th 2020

Naval G. Daver, MD, discusses the tolerability of magrolimab plus azacitidine in patients with acute myeloid leukemia and myelodysplastic syndrome.

Dr. Daver on the Advancing Treatment Landscape in AML

July 16th 2020

Naval G. Daver, MD, discusses the advancing treatment landscape in both acute myeloid leukemia and acute lymphoblastic leukemia.

Dr. Daver on the Utility of Maintenance Therapy in AML

July 15th 2020

Naval G. Daver, MD, discusses the utility of maintenance chemotherapy in acute myeloid leukemia.

Dr. Daver on Updated Findings With Magrolimab/Azacitidine in MDS

July 10th 2020

Naval G. Daver, MD, discusses updated findings on the combination of the investigational CD47-directed antibody magrolimab and azacitidine in myelodysplastic syndrome.

Dr. Daver on Anticipated Breakthroughs in AML

May 15th 2020

Naval G. Daver, MD, discusses anticipated breakthroughs in acute myeloid leukemia (AML).

Dr. Daver on Anticipated Breakthroughs in AML

May 15th 2020

Naval G. Daver, MD, discusses anticipated breakthroughs in acute myeloid leukemia (AML).

Dr. Daver on Results of a Combination Study With Azacitidine/Nivolumab in AML

March 6th 2020

Naval G. Daver, MD, discusses the results of a phase Ib/II study that evaluated the combination of azacitidine and nivolumab (Opdivo) in patients with relapsed/refractory acute myeloid leukemia.

Dr. Daver on Azacitidine and Nivolumab in Acute Myeloid Leukemia

February 26th 2020

Naval G. Daver, MD, discusses the rationale of azacitidine and nivolumab in acute myeloid leukemia.

Dr. Daver Compares Toxicity Profiles of TKIs in CML

August 29th 2019

Naval G. Daver, MD, associate professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses safety differences between the TKIs ponatinib, dasatinib (Sprycel) and nilotinib (Tasigna) in the treatment of patients with chronic myeloid leukemia.

Dr. Daver Discusses Use of MRD Assessment in Hematologic Malignancies

March 2nd 2019

Naval G. Daver, MD, discusses the role of minimal residual disease assessment in the treatment of patients with hematologic malignancies.